CDK9-IN-7
CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM) . CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC[1].
Product Specifications
CAS Number
2369981-71-3
UNSPSC
12352005
Target
Apoptosis; CDK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk9-in-7.html
Purity
98.05
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C(N(C)C)C1=CC2=CN=C(NC3=CC=C(NC(CCCCCCCN=C=S)=O)C=C3)N=C2N1C4CCCC4
Molecular Formula
C29H37N7O2S
Molecular Weight
547.71
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK4; CDK6; CDK9
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Thyroglobulin (2H11), CF640R conjugate, 0.1mg/mL
Rat WW domain binding protein 4 (WBP4) ELISA Kit
Anti-Human/Mouse CD45R/ B220 Antibody [RA3-6B2], PE-Cy7-100ug
